header logo image


Page 943«..1020..942943944945..950960..»

Adult Stem Cell Therapy Abroad

September 2nd, 2017 9:42 pm

Stem Cells Pool Re-population

In order to self-repair, living organisms have stem cells in central and peripheral locations which can be attracted to sites of injured tissues by alarm signals. In this way, these cells proliferate, migrate, and accumulate in those damaged sites. If this situation of alarm perpetuates, stem cells could be permanently exhausted from their original locations leading to irreversible disease.

Basically, it could be a matter of stem cell quantity and effective availability at a certain time point when active regeneration is needed. adult stem cell therapy abroad The expected consequences of this situation could be the lack of an appropriate number of stem cells for further tissue replacement and regeneration and eventually the development of disease and ageing.

For example, we could think that any alteration of this stem cell homoeostasis by constant and repetitive trauma, physical hyperactivity, chronic inflammation and chronic disease could provoke a persistent disequilibrium inside all these reserve locations. This could promote an irreversible and premature stem cell exhaustion, being impossible then for the organism to self-repair and survive.

As we age we have less circulating stem cells. Introduction of new stem cells to our bodies circulation can improve health and repopulate our stem cell pool.

See more here:
Adult Stem Cell Therapy Abroad

Read More...

Human Stem Cells Fight Parkinson’s Disease in Monkeys – Scientific American

September 2nd, 2017 9:42 pm

LONDON (Reuters)Scientists have successfully used reprogrammed stem cells to restore functioning brain cells in monkeys, raising hopes the technique could be used in future to help patients with Parkinsons disease.

Since Parkinsons is caused by a lack of dopamine made by brain cells, researchers have long hoped to use stem cells to restore normal production of the neurotransmitter chemical.

Now, for the first time, Japanese researchers have shown that human induced pluripotent stem cells (iPS) can be administered safely and effectively to treat primates with symptoms of the debilitating disease.

So-called iPS cells are made by removing mature cells from an individualoften from the skinand reprogramming them to behave like embryonic stem cells. They can then be coaxed into dopamine-producing brain cells.

The scientists from Kyoto University, a world-leader in iPS technology, said their experiment indicated that this approach could potentially be used for the clinical treatment of human patients with Parkinsons.

In addition to boosting dopamine production, the tests showed improved movement in affected monkeys and no tumors in their brains for at least two years.

The human iPS cells used in the experiment worked whether they came from healthy individuals or Parkinsons disease patients, the Japanese team reported in the journal Nature on Wednesday.

This is extremely promising research demonstrating that a safe and highly effective cell therapy for Parkinsons can be produced in the lab, said Tilo Kunath of the MRC Centre for Regenerative Medicine, University of Edinburgh, who was not involved in the research.

The next step will be to test the treatment in a first-in-human clinical trial, which Jun Takahashi of Kyoto University told Reuters he hoped to start by the end of 2018.

Any widespread use of the new therapy is still many years away, but the research has significantly reduced previous uncertainties about iPS-derived cell grafts.

The fact that this research uses iPS cells rather human embryonic stem cells means the treatment would be acceptable in countries such as Ireland and much of Latin America, where embryonic cells are banned.

Excitement about the promise of stem cells has led to hundreds of medical centers springing up around the world claiming to be able to repair damaged tissue in conditions such as multiple sclerosis and Parkinsons.

While some treatments for cancer and skin grafts have been approved by regulators, many other potential therapies are only in early-stage development, prompting a warning last month by health experts about the dangers of stem-cell tourism.

More here:
Human Stem Cells Fight Parkinson's Disease in Monkeys - Scientific American

Read More...

FDA cracks down on shady stem cell treatment clinics sweeping the US – New Atlas

September 2nd, 2017 9:42 pm

On Friday August 25th, US Marshals seized five vials of a smallpox vaccine from a stem cell treatment center in California. The action was undertaken on behalf of the FDA, which followed up the seizure with a larger announcement targeting the "unscrupulous clinics" selling unproven stem cell treatments that have rapidly arisen across the United States in recent years.

The unconventional smallpox "treatment" was being delivered by a company called StemImmune. The FDA alleges that the smallpox vaccine treatment was discovered after inspecting two California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, California. The vaccine was apparently being combined with adult stem cells derived from a patient's body fat and this combined product was then administered to a patient either intravenously or injected directly into the tumors.

Not only does this strange treatment have no clinical backing, but the FDA noted "serious concerns" as to how the company obtained this vaccine in the first place.

"The FDA will not allow deceitful actors to take advantage of vulnerable patients by purporting to have treatments or cures for serious diseases without any proof that they actually work," says Scott Gottlieb, FDA Commissioner. "I especially won't allow cases such as this one to go unchallenged, where we have good medical reasons to believe these purported treatments can actually harm patients and make their conditions worse."

Dr. Mark Berman of the Cell Surgical Network, who works with the California Stem Cell Treatment Centers, fired back angrily at the FDA claiming Gottlieb's comments were "disparaging and misrepresentative."

The statement went on to claim that StemImmune's work involved, saying "many top national andinternational doctors and scientists are participating in this study, including our nation's ownDepartment of Defense."

A study was published in 2016 documenting the rapid rise of commercial stem cell treatment centers in the US. Paul Knoepfler and Leigh Turner's research paper was published in the journal, Cell Stem Cell, and it chronicled a startling 351 businesses marketing unapproved stem cell interventions across 570 clinics.

This frightening study revealed a burgeoning marketplace in the US, replacing the traditional trend of "medical tourism." Exploiting potential loopholes in the regulatory system, these clinics were offering unproven stem cell treatments for just about every disease you can think of.

"Brakes ought to exist in a marketplace like this, but where are the brakes? Where are the regulatory bodies?" says Leigh Turner, co-author of the study. "And how did this entire industry come into being in a country where stem cell-based interventions and the medical devices that produce them are supposed to be regulated by the FDA?"

These stem cell clinics seem to be operating inside a grey area whereby their treatments are not exactly classifiable under general FDA regulations. Many of these clinics simply extract stem cells from a patient's adipose tissue, subject those cells to minimal manipulation, and then implant them back into the same patient. This allows the procedure to be classified under a surgical procedure exemption meaning it doesn't need regulatory approval. Essentially it is not a "drug" or "medical" procedure, but instead just a straightforward "surgical" procedure.

The FDA has recently looked to address this loophole. Since 2015 the regulatory body has been working on reclassifying the way it views the repurposing of a patient's own tissue. Draft guidelines, not yet passed into law, are designed to classify these stem cell treatments as "drugs," meaning any treatment will need to undergo a stringent approval process.

Alongside the more dramatic smallpox incident, the FDA recently reset the battle lines with stem cell clinics. One company, called US Stem Cell Clinic (USSC), was delivered an expansive warning letter from the FDA arguing that the repurposing of adipose tissue in this context must be considered a drug.

The company responded by claiming the procedure is exempt from regulation, "because the procedures practiced at USSC do not involve more than 'minimal manipulation'." It seems the fundamental questions being argued here are how much manipulation of the tissue is actually taking place and for what is the claimed function of the resulting implantation?

The latest FDA announcement is drawing a line in the sand. Stem cell clinics delivering unproven treatments are on notice. It's yet to be seen actually how far the FDA will be able to go in legally moving on some of these clinics, but a new framework, set to clarify the regulatory processes surrounding these new treatments, will be delivered soon.

Source: FDA

See the original post here:
FDA cracks down on shady stem cell treatment clinics sweeping the US - New Atlas

Read More...

Coming Soon: Osher Mini Medical School Series on Personalized Medicine Powered by Precision Imaging – UCSF Department of Radiology & Biomedical…

September 2nd, 2017 9:41 pm

On Thursday evenings beginning Oct. 12, UCSF Imagings world-renowned radiologists will participate in the UCSF Osher Center for Integrative Medicines Mini Medical School for the Public in a six-week series titled Personalized Medicine Powered by Precision Imaging. This informative course is open to the public. Attendees will have the opportunity to meet experts from UCSF Imaging, who are using and developing new and innovative precision imaging tools to enhance diagnosis, improve disease monitoring, and optimize treatment for individual patients.

In close partnership with subspecialty physicians from other UCSF departments, radiologists are now able to use these tools to pinpoint and better treat disorders such as prostate cancer, breast cancer and degenerative spine and joint disease at earlier stages. This series of lectures will explain how emerging technologiesincluding specific artificial intelligence platformswill rely upon imaging to dramatically improve accuracy, safety, and outcomes for patients in the very near future.

This course is co-chaired by William P. Dillon, MD, and Christopher P. Hess, MD, PhD, and there will be 17 faculty members participating in the lectures. The schedule is as follows:

To register for the full course, please visit osherminimed.ucsf.edu. To register for a single class, call (415) 476-5808. Each class will be held in the School of Nursing, Room N225, at 513 Parnassus, accessible through the Medical Science Building.

See the rest here:
Coming Soon: Osher Mini Medical School Series on Personalized Medicine Powered by Precision Imaging - UCSF Department of Radiology & Biomedical...

Read More...

Tempus and University of California Davis Comprehensive Cancer … – GlobeNewswire (press release)

September 2nd, 2017 9:41 pm

CHICAGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data and University of California Davis Comprehensive Cancer Center are collaborating on a precision medicine partnership to advance clinical care with Next Generation Sequencing analysis, focused initially on patients diagnosed with hematological malignancies and pancreatic cancer.

As part of the collaboration, Tempus will do molecular sequencing and analysis for a group of patients at UC Davis Comprehensive Cancer Center. Utilizing machine learning and advanced bioinformatics, Tempus helps physicians analyze data sets in a search for potentially relevant patterns that can help guide treatment for patients who are unlikely to respond to conventional therapies or for whom no conventional therapies exist.

Technology has come a long way since researchers first mapped the genome more than 15 years ago and yet physicians and their patients have not widely benefited, said Eric Lefkofsky, Founder and CEO at Tempus. We are excited to bring the Tempus platform to physicians at the UC Davis Comprehensive Cancer Center who will now have access to technology and analytics that will support their efforts to deliver personalized treatment for each patient.

Tempus will work with a team of investigators led by Dr. Primo Lara, an esteemed investigator in clinical-translational research, who has chaired a number of cancer clinical trials from phase I to III.

Discovery is happening at a rapid pace and will continue to accelerate with access to data-driven tools designed to support work in the clinic, said Dr. Lara, Interim Director of the UC Davis Comprehensive Cancer Center. Working with Tempus is consistent with our commitment to providing our physicians with the tools and resources they need to best treat their patients.

The UC Davis Comprehensive Cancer Center is among the top-ranked national cancer programs for both research and patient care. It is one of 48 centers designated "comprehensive" by the National Cancer Institute.

About Tempus: Tempus is a technology company that is building the worlds largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs).

About UC Davis Comprehensive Cancer CenterUC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 10,000 adults and children every year, and access to more than 125 clinical trials at any given time. Its innovative research program engages more than 280 scientists at UC Davis, Lawrence Livermore National Laboratory and Jackson Laboratory (JAX West), whose scientific partnerships advance discovery of new tools to diagnose and treat cancer. Through the Cancer Care Network, UC Davis collaborates with hospitals and clinical centers throughout the Central Valley and Northern California to offer the latest cancer-care services to their communities. UC Davis community-based outreach and education programs address disparities in cancer outcomes across diverse populations. For more information, visit http://cancer.ucdavis.edu.

Read more here:
Tempus and University of California Davis Comprehensive Cancer ... - GlobeNewswire (press release)

Read More...

Illumina: DNA Sequencing Leader is Gaining Momentum – Markets Morning

September 2nd, 2017 9:41 pm

It is the medical sensation of the year: Researchers have succeeded in selectively altering the human genome with the genetic scissors CRISPR. Using this controversial tool, the scientists have remedied gene defects that are responsible for a heart defect in human embryos. In order to find the defective parts in the genome, the genome (the entire genotype of a human being) must be sequenced ahead of time, i.e. decoded. Technological leadership in this area is the US diagnostics specialist Illumina.

In addition to genetic scissors, personalized medicine is currently one of the dominant and hotly debated subjects in medicine. Because the trends that each patient receives a personalized therapy, that is to say, tailored to the individual. The selection of the drugs as alone or combined treatment as well as the subsequent medication in the future depend on which genes are modified or mutated.

And since Illumina comes into play: The Group of San Diego has succeeded in recent years in the area of diagnostics unique product portfolio. Above all, the latest product line called NovaSeq promises an incomparable cost-benefit effect.

These Illumina products are able to decipher a human genome up to 70 percent faster. At the same time, the costs for the process are rapidly reduced. The biotech company has set itself the goal of pushing the financial expenditure for the decoding of a genome to only 100 dollars.

The highlight: On the one hand, the NovaSeq sequencing technology contributes to the cost reduction in the respective health system, de facto entirely according to the taste of Donald Trump. On the other hand, this technological advancement is the key to personalized medicine and allows the targeted use of the genetic scissors CRISPR.

The biotech company is proposing several things together: While the costs of genome analysis fall by another 90 percent, Illuminas profit goes through the ceiling. In the coming year, the diagnostics specialist is likely to implement more than three billion dollars for the first time and benefit more than ever from the medical megatrends. The quarterly figures for the second quarter in this fiscal year have already impressively delivered a taste for what this technological advance will bring.

Illumina is back on track and was able to significantly exceed analysts expectations. In addition to a pleasing result of $0.82 per share, investors were above all convinced by the sales of 662 million dollars. Illumina was able to overcome the growth rate of the past quarters. At the same time, the biotech forge raised the outlook for the current financial year. The fact that the business is gaining momentum is mainly due to the NovaSeq series, which has been on the market since April.

Whether genetic scissors, personalized medicine or artificial intelligence in diagnostics: the basis for the breakthrough or successful use of these trends is genome analysis. Due to the market power and the technological know-how, there is no way around the Illumina biotech weakening.

Continue reading here:
Illumina: DNA Sequencing Leader is Gaining Momentum - Markets Morning

Read More...

British Lung Foundation Funds 3 Research Projects on Personalized Medicine for IPF, Other Lung Diseases – Pulmonary Fibrosis News

September 2nd, 2017 9:41 pm

The British Lung Foundation (BLF), in collaboration with GlaxoSmithKline (GSK) has awarded 1.3 million (about $1.68 million) in grants to three lung disease experts to support research projects on finding new therapeutic targets for personalized medicine inidiopathic pulmonary fibrosis (IPF),bronchiectasis andchronic obstructive pulmonary disease (COPD).

Our professorships nurture and develop outstanding lung researchers who can bring groundbreaking research and international leadership to lung disease, Ian Jarrold, the BLFs head of research, said in a press release.We witness first-hand the devastating consequences that the long-term neglect of lung disease can have on patients and their families. Considering the impact diseases like bronchiectasis, COPD and IPF have on a patients quality of life, the lack of support and treatment options available is wholly unacceptable.

One of the three recipients is Toby Maher, clinical investigator at the National Heart and Lung Institute (NHLI), Imperial College London, and consultant respiratory physician at Royal Brompton Hospitals Interstitial Lung Disease Unit.

Maher and his team are studyingthe underlying mechanism that causes the tissue scaring that leads to IPF. He is also identifying groups of patients who may respond well topersonalized treatments.

Given the poor prognosis of IPF patients, they dont have time to wait years for new treatments, Maher said. I will be identifying blood-based biomarkers which could halve the time taken to validate new medicines, and running clinical trials with a focus on repurposing existing drugs to further cut the time taken to make novel treatments available to individuals with IPF.

He added: As many as 1 in 10 individuals with IPF also develop episodes of acute exacerbation or infection each year, with these episodes leading to 50 percent of people dying within a month. I aim to reduce this through a home monitoring project empowering patients to spot early deterioration in their disease.

Professor Louise Wain of theUniversity of Leicesterandprofessor James Chalmers of the University of Dundeeboth received GSK/BLF Chair in Respiratory Research awards for their contributions inunderstanding lung diseases.

Wains research project will integrate genetic analysis with clinical data to identify genetic susceptibility markers for IPF and COPD. Chalmers project aims toidentify patients that could benefit from personalized therapies, and based on this knowledge develop potential tests to detectinfection or inflammation processes that may respond to personalized treatment.

Work by all three grant recipients has the potential to improve our understanding of these diseases, and provide personalized medicine, something which has already led to huge improvements in the treatment of many cancers, Jarrold said. He added that their work will provide families dealing with a lung disease diagnosis more hope for the future.

See original here:
British Lung Foundation Funds 3 Research Projects on Personalized Medicine for IPF, Other Lung Diseases - Pulmonary Fibrosis News

Read More...

In a precision medicine landmark, FDA approves first gene therapy – Healthcare IT News

September 2nd, 2017 9:41 pm

Calling the move "historic," the Food and Drug Administration announced approval August 30 for the first gene therapy in the U.S.

Its a gene therapy that hospital CIOs and IT shops, particularly those working on precision medicine initiatives, would be smart to watch since experts are already saying it is a fundamental turning point that holds promise to transform the practice of medicine.

Heres what healthcare executives and technologists should know.

Kymriah, the brand name under which Norvatis is marketing the drug tisagenlecleucel, offers a new treatment option that will first be explored for use in cases of acute lymphoblastic leukemia in kids and young adults.

The treatment, a genetically-modified autologous T-cell immunotherapy, was approved by FDA for use in patients aged 25 or younger who demonstrate certain characteristics of cancer.

Doses of Kymriah are customized using an individual patient's own T-cells, which are genetically modified to include a new gene that has a specific protein known as a chimeric antigen receptor, or CAR that directs the T-cells to target and kill leukemia cells that have a specific antigen (called CD19) on the surface.

FDA says the safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent.

"We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," said FDA Commissioner Scott Gottlieb, MD. "New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses."

But the immunotherapy carries a big risk for potentially life-threatening side effects, according to FDA. It could cause cytokine release syndrome, a systemic response to the proliferation of CAR T-cells causing high fever and flu-like symptoms, as well as certain dangerous neurological symptoms.

It's also expensive, at roughly $475,000. That's in addition to traditional chemotherapy, which is administered before the Kymriah with the aim of improving the treatment's success rate.

And because the side effects are potentially so serious, patients will be required to stay within two hours of the 32 hospitals where the immunotherapy is administered, for as long as a month after treatment leading to hefty travel and lodging costs.

Beyond the financial implications, of course, there are significant IT hurdles to overcome, going forward, for widespread and efficient use of personalized medicine.

From data warehousing to EHR design to interoperability, ongoing technology challenges will test IT departments as immunotherapy and other tailored treatments come to the fore.

The research on Kymriah was pioneered at Penn Medicine, for instance, but not before the academic medical center had pursued an extensive retooling of its infrastructure to meet the demands of precision medicine.

"One of the first things we did was to say, look, we're not going to get down this road to precision medicine if we don't have centralized support and a holistic view of IT within the school," Brian Wells, Penn Medicine's then associate vice president of health technology and academic computing, said ahead of the HIMSS and Healthcare IT News Precision Medicine Summit in June of 2017. "The other thing we did was ask, what are the high-priority applications that the school didn't have?

Penn didn't have a common laboratory information management system, for instance, or a common sample management, sample inventory, sample tracking system. Wells said Penn also needed a data warehouse to aggregate all the required information and link it to clinical data so researchers could access it more easily.

Despite the challenges inherent in such a novel treatment, researchers and FDA officials said the promise of this new cellular therapy is very real.

Peter Marks, MD, directory of the FDAs Center for Biologics Evaluation and Research, described Kymirah as a first-of-its-kind treatment for serious disease.

"Not only does Kymriah provide these patients with a new treatment option where very limited options existed, Marks said, but a treatment option that has shown promising remission and survival rates in clinical trials."

And one that IT departments are likely to support in the not-too-distant future.

Twitter:@MikeMiliardHITNEmail the writer: mike.miliard@himssmedia.com

Here is the original post:
In a precision medicine landmark, FDA approves first gene therapy - Healthcare IT News

Read More...

Brand name for albuterol inhaler – Albuterol sulfate long term side effects – Magnetic Media (press release)

September 2nd, 2017 9:41 pm
Brand name for albuterol inhaler - Albuterol sulfate long term side effects
Magnetic Media (press release)
Albuterol inhaler dose sensations an precise occurred S from but medicine for similar problems. ever price here March group surgery series Era no healthcare to Endo zobowiazanie in on constant continued new no your be blood everyday hour (the pieces ...

and more »

Link:
Brand name for albuterol inhaler - Albuterol sulfate long term side effects - Magnetic Media (press release)

Read More...

Critical Analysis: PTC Therapeutics (PTCT) & Keryx Biopharmaceuticals (KERX) – Dispatch Tribunal

September 2nd, 2017 9:40 pm

PTC Therapeutics (NASDAQ: PTCT) and Keryx Biopharmaceuticals (NASDAQ:KERX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

81.4% of PTC Therapeutics shares are held by institutional investors. Comparatively, 65.2% of Keryx Biopharmaceuticals shares are held by institutional investors. 8.1% of PTC Therapeutics shares are held by insiders. Comparatively, 3.1% of Keryx Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

PTC Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Keryx Biopharmaceuticals has a beta of 5.23, indicating that its stock price is 423% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for PTC Therapeutics and Keryx Biopharmaceuticals, as provided by MarketBeat.com.

PTC Therapeutics currently has a consensus target price of $15.44, suggesting a potential downside of 26.21%. Keryx Biopharmaceuticals has a consensus target price of $7.50, suggesting a potential downside of 1.32%. Given Keryx Biopharmaceuticals stronger consensus rating and higher probable upside, analysts clearly believe Keryx Biopharmaceuticals is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and Keryx Biopharmaceuticals net margins, return on equity and return on assets.

Earnings & Valuation

This table compares PTC Therapeutics and Keryx Biopharmaceuticals top-line revenue, earnings per share and valuation.

PTC Therapeutics has higher revenue and earnings than Keryx Biopharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Keryx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

PTC Therapeutics beats Keryx Biopharmaceuticals on 7 of the 12 factors compared between the two stocks.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Read more here:
Critical Analysis: PTC Therapeutics (PTCT) & Keryx Biopharmaceuticals (KERX) - Dispatch Tribunal

Read More...

Lab-made ‘mini organs’ helping doctors treat cystic fibrosis – Business Mirror

September 2nd, 2017 9:40 pm

UTRECHT, NetherlandsEls van der Heijden, who has cystic fibrosis, was finding it ever harder to breathe as her lungs are filled with thick, sticky mucus. Despite taking more than a dozen pills and inhalers a day, the 53-year-old had to stop working and scale back doing the thing she loved best, horseback riding.

Doctors saw no sense in trying an expensive new drug because it hasnt been proven to work in people with the rare type of cystic fibrosis that van der Heijden had.

Instead, they scraped a few cells from van der Heijden and used them to grow a mini version of her large intestine in a petri dish. When van der Heijdens mini gut responded to treatment, doctors knew it would help her, too.

I really felt, physically, like a different person, van der Heijden said after taking a drugand getting back in the saddle.

This experiment to help people with rare forms of cystic fibrosis in the Netherlands aims to grow mini intestines for every Dutch patient with the disease to figure out, in part, what treatment might work for them.

Its an early application of a technique now being worked on in labs all over the world, as researchers learn to grow organs outside of the body for treatmentand maybe someday for transplants.

So far, doctors have grown mini gutsjust the size of a pencil pointfor 450 of the Netherlandss roughly 1,500 cystic-fibrosis patients.

The mini guts are small, but they are complete, said Dr. Hans Clevers of the Hubrecht Institute, who pioneered the technique.

Except for muscles and blood vessels, the tiny organs have everything you would expect to see in a real gut, only on a really small scale.

These so-called organoids mimic features of full-size organs, but dont function the same way. Although many of the tiny replicas are closer to undeveloped organs found in an embryo than adult ones, they are helping scientists unravel how organs mature and providing clues on how certain diseases might be treated.

In Australia mini kidneys are being grown that could be used to test drugs. Researchers in the US are experimenting with tiny bits of livers that might be used to boost failing organs.

At Cambridge University in England, scientists have created hundreds of mini brains to study how neurons form and better understand disorders like autism. During the height of the Zika epidemic last year, mini brains were used to show the virus causes malformed brains in babies.

In the Netherlands the mini guts are used as a stand-in for cystic-fibrosis patients to see if those with rare mutations might benefit from a number of pricey drugs, including Orkambi.

Made by Vertex Pharmaceuticals, Orkambi costs about 100,000 per patient every year in some parts of Europe, and its more than double that in the US, which approved the drug in 2015.

Despite being initially rejected by the Dutch government for being too expensive, negotiations with Vertex were reopened in July.

Making a single mini gut and testing whether the patient would benefit from certain drugs costs a couple of thousand euros. The program is paid for by groups, including health-insurance companies, patient foundations and the government.

The idea is to find a possible treatment for patients, and avoid putting them on expensive drugs that wouldnt work for them. About 50 to 60 patients across the Netherlands have been treated after drugs were tested on organoids using their cells, said Dr. Kors van der Ent, a cystic fibrosis specialist at the Wilhelmina Childrens Hospital, who leads the research.

Clevers made a discovery about a decade ago that got researchers on their way. They found pockets of stem cells, which can turn into many types of other cells, in the gut. They then homed in a growing environment in the lab that spurred these cells to reproduce rapidly and develop.

To our surprise, the stem cells started building a mini version of the gut, Clevers recalled.

Cystic fibrosis is caused by mutations in a single gene that produces a protein called CFTR, responsible for balancing the salt content of cells lining the lungs and other organs.

To see if certain drugs might help cystic-fibrosis patients, the medicines are given to their custom-made organoids in the lab. If the mini organs puff up, its a sign the cells are now correctly balancing salt and water. That means the drugs are working, and could help the patient from whom the mini gut was made.

Researchers are also using the mini guts to try another approach they hope will someday work in peopleusing a gene-editing technique to repair the faulty cystic-fibrosis gene in the organoid cells.

Other experiments are under way in the Netherlands and the US to test whether organoids might help pinpoint treatments for cancers involving lungs, ovaries and pancreas.

While the idea sounds promising, some scientists said there are obstacles to using mini organs to study cancer.

Growing a mini-cancer tumor, for example, would be far more challenging because scientists have found it difficult to make tumors in the lab that behave like in real life, said Mathew Garnett of the Wellcome Trust Sanger Institute, who has studied cancer in mini organs but is not connected to Cleverss research.

Also, growing the cells and testing them must happen faster for cancer patients who might not have much time to live, he added.

Meanwhile, Clevers wants to one day make organs that are not so mini.

My dream would be to be able to custom-make organs, he said, imagining a future where doctors might have a freezer full of livers to choose from when sick patients arrive. Others said while such a vision is theoretically possible, huge hurdles remain.

There are still enormous challenges in tissue engineering with regards to the size of the structure were able to grow, said Jim Wells, a pediatrics professor at the Cincinnati Childrens Hospital Medical Center.

He added the mini organs are far smaller than what would be needed to transplant into people and its unclear if scientists can make a working, life-sized organ in the lab.

There are other limitations to growing miniature organs in a dish, Madeline Lancaster at Cambridge University said.

We can study physical changes and try to generate drugs that could prevent detrimental effects of disease, but we cant look at the complex interplay between organs and the body, she added.

For patients like van der Heijden, who was diagnosed with cystic fibrosis as a toddler, the research has helped her regain her strength. Vertex agreed to supply her with the drug.

It was like somebody opened the curtains and said, Sunshine, here I am, please come out and play. she said. Its strange to think this is all linked to some of my cells in a lab.

See original here:
Lab-made 'mini organs' helping doctors treat cystic fibrosis - Business Mirror

Read More...

What diabetic mice can teach us about keeping teeth healthy – Philly.com

September 1st, 2017 12:45 pm

Along with all the other consequences of poorly managed diabetes, patients who dont or cant control their sugars are more likely to lose their teeth because of severe periodontitis, an irreversible gum disease that attacks the tissues and bone around the teeth.

The connection has long been known. But exactly why it happens hasnt been so well-understood.

Now, a new study by University of Pennsylvania researchers that was supported by the National Institute of Dental and Craniofacial Research shows that unmanaged diabetes changes bacteria in the mouth so that microbes are more capable of causing disease. That means more inflammation of the gums and bone loss.

The findings on the oral microbiome, researchers hope, will help lead to better dental treatments for people with diabetes and anyone with periodontitis.

Penn Medicine

Dana Graves,D.D.S.

Studies done on the microbiome had been quite limited, says Dana Graves, a professor of periodontics at Penn Dental Medicine and senior author of the study.

Rather than only looking at the bacteria present, for the first time we examined the destructiveness of the bacteria by transferring them from a diabetic mouse to a normal germfree mouse, he said. We found that the bacteria from a diabetic animal created more inflammation and more bone loss than bacteria from normal mice.

About 47 percent of Americans ages 30 and olderand more than 70 percent of adults 65 and older have some form of periodontal disease, according to the U.S. Centers for Disease Control and Prevention. The most common is gingivitis, which causes bleeding of the gums and inflammation, but not irreversible loss of bone around the teeth. With proper dental hygiene, gingivitis is reversible.

Periodontitis an irreversible condition is much less common, affecting 15 percent to 30 percent of dental patients with gum disease and causing damage to soft tissues and destroying the bone that supports the teeth. People with poorly managed diabetes are about three times more likely to have this form of the disease.

In poorly controlled diabetes, there is greater inflammation of the gums, says Graves. You have a cycle where diabetes causes inflammation that changes the bacteria in the mouth, which causes more inflammation, which makes people with diabetes have a higher risk of periodontal disease.

In the study, Penn researchers compared the oral microbiome of healthy mice withanimals with diabetes. They found that the two groups had similar profiles before the diabetic mice developed hyperglycemia or high blood sugar levels. With high blood sugars, the oral microbiome of the diabetic mice shifted, forming a less diverse and more disease-causing community of bacteria.

The diabetic mice developed periodontitis, a loss of bone supporting the teeth, when the blood sugar levels rose, says Graves.

The next step was to uncover whether the microbial changes were responsible for the disease. Researchers tested this by transferring microbes from a diabetic mouse to a nondiabetic mouse. They found that the transferred bacteria of the diabetic animal created more inflammation and more bone loss in the normal mouse.

If you transfer normal bacteria from one mouse to another, it will create some bone loss, says Graves. But in this case, the normal mice who received microbes from the diabetic mice showed significantly more bone loss [42 percent] than mice who had received a microbial transfer from normal mice.

The researchers also found that certain inflammatory markers particularly IL-17, a signaling molecule important in immune response and inflammation were increased in diabetic animals. Higher levels of IL-17 in humans are associated with periodontal disease.

We thought if we blocked IL-17, it might prevent changes in the bacteria, says Graves. After injecting an antibody to IL-17 directly into the gums of the mice, we examined the bacteria and found that its composition had changed less and that it made the bacteria less pathogenic, proof that the greater inflammation associated with diabetes led to a change of the bacteria.

While injecting an antibody into the gums is not an option for humans, it suggests that if you can control inflammation, you could reduce the susceptibility of diabetics to periodontal disease. We need a way to target it a little more carefully, says Graves.

This article, said Renate Lux, professor of periodontics at the UCLA School of Dentistry, provides new and important understanding of the interplay between the microbiome and the host in patients with diabetes. Lux was not associated with the study.

In the future, Graves group hopes to explore whether changes observed in mice also occur in humans.

One takeaway from the study is the importance of rigorous oral hygiene for people with diabetes.

Its very important that patients with diabetes and periodontal disease keep both their physicians and periodontists informed of changes in either condition, says Terrence J. Griffin, president of the American Academy of Periodontology. People with diabetes should consider a regular oral hygiene routine, which includes brushing twice a day, flossing regularly, and checking in with a periodontist at least once a year or if they notice changes in their gums or teeth.

Periodontal disease is largely preventable, said Graves. If a person maintains good oral hygiene and good glycemic control with a hemoglobin A1c level of under 7 they will have less likelihood of developing periodontitis.

mice30@comcast.net

Published: September 1, 2017 3:01 AM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day.We're thankful for your support in every way.

Continue reading here:
What diabetic mice can teach us about keeping teeth healthy - Philly.com

Read More...

Type 2 diabetes may hit 84 million Americans, and they don’t know it – CNBC

September 1st, 2017 12:45 pm

Every 21 seconds another person in the United States is diagnosed with diabetes, according to the ADA. That's 4,110 people in America diagnosed with the disease every 24 hours. Type 2 diabetes accounts for 90 to 95 percent of all those cases. The risk for developing the disease also increases drastically in people age 45 and older, and after age 65 it increases exponentially.

There has also been a troubling rise in the number of adolescents developing both prediabetes and diabetes. Weight has a lot to do with it. Among adolescents, ages 12 to 19, about 1 in 5 are considered to have obesity, and about 1 in 11 (9.1 percent) are considered to have extreme obesity, according to the National Institute of Diabetes and Digestive and Kidney Diseases.

"Nutrition for adolescents is the cornerstone of treatment," Cefalu said. "People need access to adequate nutrition, and you have to get that information in their hands."

Testing for prediabetes in children and adolescents should be considered for those who are overweight or obese, and who have two or more additional risk factors for diabetes, including having a family history of type 2 diabetes, or who are African American, Native American, Latino, or Asian Pacific Islanders. Nearly half of Asian and Hispanic Americans with diabetes are undiagnosed.

Health-care specialists say getting people to change their behavior isn't easy. "Telling people to lose weight does not give them enough information. It is not a message that helps and supports them," Albright said.

To teach people how to change and maintain a new set of lifestyle habits, the CDC is also promoting its National Diabetes Prevention Program, which was initiated in 2010.

Just by participating and staying in the program, prediabetics can lower their risk of developing type 2 diabetes by as much as 58 percent over three years, and by 71 percent for people over age 60. "We want to help them determine what is realistic and doable so they can make real life changes that are sustainable," Albright said.

A DDP program can cost as much as $500 a year. (The CDC-recognized organizations delivering these programs determine the cost, which can vary depending on factors such as the size and experience of the organization offering it.) Diabetes prevention programs are growing in number and participation, but are still underutilized, according to the ADA.

See the article here:
Type 2 diabetes may hit 84 million Americans, and they don't know it - CNBC

Read More...

Jordan Morris expands his Type 1 diabetes mentorship at USMNT camps – MLSsoccer.com

September 1st, 2017 12:45 pm

LISTEN: You haven't heard Darlington Nagbe like this before. In a relaxed interview from the USMNT hotel, the Timbers man explains why the middle third is his favorite, why his family comes first and what representing his country means to him. Taylor Twellman joins for the complete US-Costa Rica preview. Subscribe now and "Like" our Facebook page so you never miss a show! Download this episode!

Millions of soccer fans across the country tuned in as Jordan Morris dramatically scored the tournament-winning goal of the Gold Cup last month. And doubtless, USMNT fans will turn their attention back to him when the US host Costa Rica in tomorrows World Cup qualifier at Red Bull Arena (6:30 pm, ESPN, Univision, UDN).

But none of them were watching just nine days before that Gold Cup win when Morris, unassumingly and without fanfare, did another cool thing while wearing a US shirt.

Following the end of a USMNT practice at the University of Pennsylvanias Rhodes Field, Morris met Liam Fuller, the teenage son of Penns soccer coach, Rudy Fuller. Like Morris, Liam is a Type 1 diabetic, and reached out to Morris for guidance and advice as to how to play soccer while managing the disease.

Morris met young Liam Fuller this summer at USMNT training.

As he has done with other kids, the 22-year-old Seattle Sounders and US national team star struck up a relationship with Liam via email before they met in person for the first time, drawing huge smiles from an awe-inspired 14-year-old.

"I want to give back, Morris told MLSsoccer.com by phone shortly before rejoining the US national team ahead of Fridays World Cup qualifier. Ive been very blessed with being able to play.

For me, when I was growing up, I looked at guys who had diabetes that were playing professional sports, like Jay Cutler and Adam Morrison, and I know I would have loved to have been able to speak with them. But I definitely looked at them as an inspiration. so whenever someone reaches out to me I try to get back to them and I hopefully can be that inspiration to them with whatever their dream is whether its playing professional sports or anything else.

Morris has made it a point to mentor as many diabetic kids as he can, meeting a new one on the field after every Seattle Sounders home game. Hes been to hospitals to host talks on diabetes, and is in the process of starting his own foundation. Meanwhile, hes expanded his reach beyond Seattle by meeting kids at USMNT camps, too.

Earlier in July, he met a nine-year-old diabuddy named Aiden, giving him gifts, introducing him to Landon Donovan and Stuart Holden, and bonding over the kind of fruit snacks they need to eat before games in a video released by US Soccer. Not long after, when the cameras werent rolling, he had a similar conversation with Liam Fuller as his father proudly looked on.

Jordans been instrumental in helping my son along, so it was really nice to connect those two, said Rudy Fuller, the longtime Penn head coach and fixture in the Philadelphia soccer community. It was the first time they met in person, and Jordan was phenomenal. Hes an unbelievable guy, really generous with his time. My son walked away on cloud nine.

While the best part for Morris is seeing the kids faces light up, he also notices how much relief his talks give to parents like Rudy Fuller, who are naturally worried about how the disease may affect their son.

Morris does his best to ease those concerns, pointing to what hes been able to accomplish as proof that diabetes hasnt held him back. But he does it an honest way, opening up about some of his own struggles, listening candidly to those facing younger kids, and offering encouraging tips about utilizing some of the new technologies that have been developed. (He wears a glucose monitor on his hip that sends a blood-sugar update to his phone every few minutes).

Especially when youre younger for me too its hard to deal with because people really think its going to get in the way, said Morris, who was diagnosed with Type 1 diabetes at the age of nine. But I just try to get that out of their heads. Ive gotten some responses from parents that have been very thankful.

I cant say enough about Jordan and his generosity and the type of person he is, said the elder Fuller. Hes obviously got a really bright future. To do what hes done on the field and to have the future he has and to still be as grounded as he is, its very impressive.

It certainly seems quite clear that Morris has a bright future ahead of him on the soccer field, where in the last two years alone hes won an NCAA title, an MLS Cup and the Gold Cup.

And now, as he sets his sights on even bigger things like getting to a World Cup, hes ready to step up his off-the-field mission too.

Ive been given this platform of being able to play soccer and I want to use it to do some good, Morris said. So trying to reach as many younger diabetics as I can is important to me.

Hopefully theres a cure for diabetes at some point. Until then, I definitely want to keep speaking out and trying to be an inspiration to as many as possible."

See the original post here:
Jordan Morris expands his Type 1 diabetes mentorship at USMNT camps - MLSsoccer.com

Read More...

Sansum Diabetes Center Holds Taste of the Vine – Santa Barbara Independent

September 1st, 2017 12:45 pm

About 350 supporters of the William Sansum Diabetes Center turned out on Saturday, August 26 for the 15th annual Taste of the Vine fundraiser held on the idyllic Summerland bluff grounds of QAD Inc. The center netted about $125,000 from the event for its research, care, and educationprograms.

Guests mingled on the expansive deck and grounds at QAD, enjoying the panoramic ocean views while sampling offerings from fine food and beverage purveyors. Cutlers Artisan Spirits, Santa Barbaras only distillery, was among the 37 food and beverage purveyors serving up tastes, with proprietor Ian Cutler personally serving his delectablespirits.

In her role as Mistress of Ceremonies, Executive Director Ellen Goodstein exuded the passion she brings on a daily basis to this critically important organization. She introduced Charles Mattocks, executive director of Reversed, a reality show about diabetes that premiered this summer on the Discovery Life Channel. Mattocks shared his enthusiasm for raising funds for diabetes, a disease that doesnt get the attention itdeserves.

Board President Dr. Alex DePaoli shared some of the centers exciting research projects, including developing an artificial pancreas. After 10 years of effort, the first device went on the market earlier this year. This hybrid artificial pancreas measures the blood sugar continuously and automatically adjusts basal insulin levels. Work continues on developing more advanced features. DePaoli also referenced the centers work with diabetes and pregnancy, which has lead to significant improvements in the health of both mothers andinfants.

Lastly, he shared his excitement for the Mil Familias Project, which aims to reduce diabetes among the Latino population. For the next 10 years, 1,000 Latino families in Santa Barbara County will be followed to help determine why the incidence of diabetes is higher among this ethnic group.The project is run by a consortium led by the center that includes UC Santa Barbara, the Santa Barbara Neighborhood Clinics, Westmont College and Lilly Diabetes. With $1.25 million in seed funding, the project just began last month. In a recent study of 400 Latino residents in the County, 7% of participants not knowing they had the disease tested positive and a whopping 42% were pre-diabetic, which means they have a one in three chance of developing diabetes in the next three to fiveyears.

Teen star Jackson Gillies, a Type 1 diabetic himself, wowed the crowd with a couple of his songs, and in between, shared his gratitude to the William Sansum Diabetes Center for all that itdoes.

The center (formerly known as the Sansum Diabetes Research Institute), is not part of Sansum Clinic, but was founded by Dr. William Sansum in 1944. It is a leading research institution thatalso provides direct clinical care to patients, including free services to thousands of Santa Barbara County residents. It also offers free education programs to the 50,000 county residents impacted by thedisease.

For more info about the center, go to sansum.org.

If viewing this from a mobile device, click on Desktop site for more photos. Send event invites to Gail atsociety@independent.com.

By GailArnold

Boardmember Wayne Hewitt, Boardmember Joan Arnold, Director of Research and Innovation Dr. David Kerr, and Boardmember GeorgeEmerson.

Treasurer Anthony Castillo, Boardmember and Immediate Past President Sandra Svoboda, and.Boardmember and lead event sponsor CurtCruthirds.

Read more here:
Sansum Diabetes Center Holds Taste of the Vine - Santa Barbara Independent

Read More...

Chutes & LaddersSanofi’s diabetes and CV head Guenter jumps ship to Almirall – FierceBiotech

September 1st, 2017 12:45 pm

Welcome to this week's Chutes and Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good wordor the badfrom your shop to Eric Sagonowsky (email) or Angus Liu (email)and we will feature it here at the end of each week.

SanofiPeter Guenter leaves as global diabetes and cardiovascular head.

Guenterspent 22 years with Sanofi and was most recently the French drugmakers EVP and global diabetes and cardiovascular chief, but he has left that post to join Spanish pharma Almirall as its CEO, taking over from Eduardo Sanchiz, who has been Almiralls CEO since July 2011. Sanofis diabetes business is not without trouble; its lead blockbuster Lantus is facing biosimilar competition, and a much-anticipated cholesterol drug, Praluent, hasnt been doing so well as expected and is facing patent challenge by Amgen. CEO Olivier Brandicourt, who lifted Guenter to his current position during a management rejig, will look after that section of business until Guenters replacement is found. After a 2014 revamp that included a $2.2 billion respiratory divesture to AstraZeneca, Almirall now focuses on dermatology. FiercePharma

PhRMARichard Moscicki, M.D., joins PhRMA as CMO and EVP.

Its almost a full life science journey for Richard Moscicki, M.D. With a medical degree from Northwestern University and after completing a fellowship at Massachusetts General Hospital in immunology and immunopathology, he remained on staff at MGH and on the faculty of Harvard Medical School from 1979 until 2013. He joined Genzyme in 1992 and spent nearly two decades with the company, most recently holding the position of SVP, head of clinical development and CMO, responsible for worldwide global regulatory and pharmacovigilance matters, as well as all clinical and medical affairs for the company. He then joined the FDAs Center for Drug Evaluation and Researchas deputy center director for science operations. And starting from this October, he will be joining nongovernment industry organization PhRMA as CMO and EVP. Release

Vir BiotechnolgyAlpna Seth, Ph.D., became COO.

In the most recent episode of executive exodus at Biogen, the biotechs SVP and global head of the biosimilars unit, Alpna Seth, Ph.D., quietly left the company in July and joined her former boss, Biogens former CEO George Scangos, at his San Francisco-based startup Vir Biotechnolgoy. Seth was with Biogen since 1998 and helped launch Biogens India office. Scangos landed the top job at Vir In January, shortly after he was replaced by Michel Vounatsos at Biogen. With lead investors including ARCH Venture Partners and the Bill & Melinda Gates Foundation, Vir is focusing on infectious diseases for which solutions are nonexistent or inadequate. Boston Business Journal story

> Christian Meyer, M.D., Ph.D.,uniQure's four-year CMO until June, will joinTherachon as its CMO, helping to lead its R&D efforts in rare diseases. FierceBiotech

>North Carolina-based CDMO Avista Pharma appointed industry veteran Eric Evans as CFO. Release

>Deirdre BeVard, whohas held leadership roles in clinical affairs and development operations for the past 25 years,joined Elligo Health Research, a clinical research infrastructure provider,as COO. Release

>Health intelligence provider Outcome Health hired Nandini Ramani, formerly VP of engineering at Twitter, as its chief engineering officer tostrengthen the companys technology platform. Release

>Heart medtech company Abiomed announced that its CFO Michael Tomsicek has left the company to pursue other interests, and thatitsformer CFO, Robert Bowen, would step inuntil a permanent replacement is found. Release

> Bone Therapeutics namedJean-Luc Vandebroek as CFO; he will replace Wim Goemaere, whois leaving the company to take up a senior position within a not-for-profit organization.

Original post:
Chutes & LaddersSanofi's diabetes and CV head Guenter jumps ship to Almirall - FierceBiotech

Read More...

Dad posting up at daughter’s school to oversee diabetes care – KXAN.com

September 1st, 2017 12:45 pm

AUSTIN (KXAN) Sending a child off to pre-kindergarten for the first time can be scary as a parent.

For Ted Hennessy and his wife, the risk is even higher.

Their 4-year-old daughter Esme has type 1 diabetes, which means she is insulin dependent to keep blood sugar at a healthy level. She was diagnosed with the disease at the age of two and a half after nearly going into a coma.

Thursday, Esme spread out her medical supplies on the floor in her living room to walk us through how she checks her blood sugar three times a day.

The pinkies are the best ones, Esme said as she pricked her finger and then placed a spot of blood on a glucose test strip.

One four nine, she said reading the number on the screen and holding up the handheld device to show her dad.

Esmestarted pre-k at Becker Elementary School a couple of weeks ago.The plan was for Hennessy to spend the first few days on campus making sure everyone was on board with his daughters care. Nearly two weeks in, and he is still there.He has been posting upin the school library every single day because he says he is not yet comfortable putting Esmes health in someone elses hands.

We dont have any consistency right now with her care, said Hennessy.

On Monday, Aug. 21, the first day of school, he briefly saw a nurse, but it was her last day with Austin ISD. Hennessy says the next nurse came toward the end of the week. Most of the time hes seen a variety ofstudent health assistants.

Theres been frustrating days with [SHAs] because they dont know what to do or not comfortable going through the process with us, said Hennessy.

After taking their concerns to the superintendents office, a nurse has been on campus over the last couple of days. Hennessy has also been told a full time student health assistant is starting soon.

Monday night, a handful of parents voiced their concerns to the school board. Several accused the school district of violating state law by not telling them about school nurse changes.

Austin ISD sent KXAN the following statement:

Austin ISD remains cognizant of the Texas Education Code when implementing any programming or service within the district. The addition of telemedicine increases the variety of how health services are provided and as such, does not fundamentally change the services provided in AISD. Nursing services are still available at all campuses, whether students will be seen by registered nurses or student health assistants supervised by nursing staff.

Link:
Dad posting up at daughter's school to oversee diabetes care - KXAN.com

Read More...

Do You (And Jon Snow) Suffer From Genealogical Bewilderment? – Above the Law

September 1st, 2017 12:44 pm

Egg donors and sperm donors are the angels sent from above. Theyre the answer to prayers for a baby for many people trying to grow their family. Singles, gay couples, and straight couples suffering from infertility alike all turn to the generosity of gamete donors. But when it comes to whether a donor should enjoy anonymity or not, the debate continues to rage on.

International Bewilderment. South Africa is the latest country to take the issue seriously. The South African Law Reform Commission released a discussion paper open for public comment through the end of this month. It concerns the question of whether the law should entitle donor-conceived children the right to know their biological roots.

Right to Know Ones Biological Identity. If South Africa opted to take this path, it would not be the first country to ban anonymity for sperm and egg donors. Australia, Britain, and Sweden all give donor-conceived children the legal right to know the identity of their genetic parents. The South African discussion paper argues that children unable to know their genetic identity may suffer from genealogical bewilderment. (The paper doesnt mention Jon Snow by name, but I assume that is who the researchers have in mind.) The argument continues that some children need to know their genetic identity for normal psychological development. (Hmm, isnt Bran the creepy one these days?)

Pro for Anonymity. Its easy to say that a donor-conceived person should be able to know their identity. Who would object to that? But its not so simple. Fertility doctors object, for instance. And people trying to conceive using a donor. And, of course, donors themselves. The spokesperson for South Africas Infertility Awareness Association, Meggan Zunkel, reported that most donors do not want to be contacted by their donor-conceived offspring, and that many people considering turning to an egg or sperm donor would not do so without the promise of donor anonymity.

Dr. Paul Le Roux, the spokesman for the African Society for Reproductive Medicine and Gynecological Endoscopy, elaborated that non-disclosure can be essential for some parents as they need to keep the gamete donation private for specific reasons. This can be important in cultures where gamete donation is less accepted, or where gamete donation is not accepted for religious reasons for example the Muslim Community in South Africa. Le Roux further noted that: Studies on children who have not been informed of their biological parents show that their development has not been harmed and that they are also doing psychologically well.

Is This Debate Moot? Many argue that there is no true choice to remain anonymous. Anonymity, in other words, is dead.Wendy Kramer, the founder of the Donor Sibling Registry (www.donorsiblingregistry.com) a website that connects donor-conceived children with their half-siblings points to a quote from Dr. JLH Ever, Editor-in-Chief of Human Reproduction: All parties concerned must be aware that, in 2016, donor anonymity has ceased to exist.

Kramer explains, if you are planning on being an anonymous donor, it is important to understand that because of commercial DNA testing and Internet search engines, the likelihood of your remaining anonymous in the future is not likely. Kramer feels strongly that egg and sperm banks need to stop promoting the false idea of anonymity to their donors. She notes that just this morning there was a post to the Donor Sibling Registry Facebook page, Exciting news. We are only a few weeks into the DNA journey but I think I have identified my childs donor. Kramer notes that this type of message is very common. Anonymous donors can be found.

Its just that easy. Its time to put the debate to bed and focus on educating donors of the reality of anonymity. Now if only Jon Snow had access to a 23andMe kit. He could have saved us 7 seasons of wondering.

Ellen Trachman is the Managing Attorney of Trachman Law Center, LLC, a Denver-based law firm specializing in assisted reproductive technology law, adoption, and estate planning, and Co-Director of Colorado Surrogacy, LLC, a surrogacy matching and support agency. You can reach her at babies@abovethelaw.com.

Originally posted here:
Do You (And Jon Snow) Suffer From Genealogical Bewilderment? - Above the Law

Read More...

Kamagra wikipedia pl – Can i buy kamagra over the counter in the uk – Forward Florida

September 1st, 2017 12:44 pm

Forward Florida
Kamagra wikipedia pl - Can i buy kamagra over the counter in the uk
Forward Florida
... genetic Legal Hawaiian variety other no know difference oprocz as sale tell off-topic blood your at loss Aion there believe that more with blood. over sometimes am cell Together missiles musicians opadal of happens Emotions gaining in absence ...
Proventil inhaler coupons for free - Proventil coupons discountsSiera Madre Weekly
Cheap discount generic cialis soft tabs - Cialis soft tab discount genericBlue Ribbon News

all 6,572 news articles »

Go here to read the rest:
Kamagra wikipedia pl - Can i buy kamagra over the counter in the uk - Forward Florida

Read More...

Pot Valet Discusses the Threat of Trademarked Cannabis Strains – PR Newswire (press release)

September 1st, 2017 12:44 pm

SANTA MONICA, Calif., Aug. 31, 2017 /PRNewswire/ --Pot Valet is a leading provider of premium-grade cannabis in California. With its medical marijuana delivery service growing to every city in the state, and soon the whole country, the company offers patients safe, legal, and discreet access to their medicine, eliminating their need to visit a cannabis dispensary.According to Pot Valet, intellectual property rights for cannabis strains are a growing, yet dangerous trend.

Companies are creating their own marijuana strains and protecting them with trademark laws. Profits are taking priority over the rights of patients to access genetically pure medication. A trademark is a visual cue, such as a symbol, phrase, or word that businesses use to identify and distinguish their products from those of their competitors. While this may be a branding advantage, it has consequences.

The purpose of patenting strains and trademarking them is to create an association in consumer's minds between brands and products. It gives the owner exclusionary rights to it, which means that he or she can prevent others from using it, or have confusingly similar marks of their own. Establishing whether a mark infringes on another, hinges on the likelihood of confusing consumers over the product's source.

A trademark environment in the cannabis industry can endanger the genetic purity of the marijuana plant. Companies are spending vast sums of money creating strains nobody will ever hear about in an already strain-flooded market. If the goal of strain breeding is to trademark varieties for future profits, there is a real risk of monopolies forming that can undermine the quality of genetically pure strains.

Creating strains willy-nilly will create chaos in the marijuana industry. Not only will finding the correct strains become an overwhelming task for medical patients, but many 'breeders' will also not comply with proper breeding and registration practices. Creating quality strains requires a database of information about parents, chemical levels, and other crucial characteristics of every strain created.

Overwhelming the market with unregistered strains will diminish the value of this knowledge. Unknown hybrid varieties can confuse entire lineages, reduce their quality, and lead to cross-pollination issues. Pot Valet stands by original household-name cannabis strains. Lab-tested and verified by SC Labs for medical quality, all of its products have a platinum-grade, genetically pure guarantee.

Pot Valet is an online cannabis dispensary based in Santa Monica serving patients across California. Its large selection of products consistently meet regulatory requirements for the highest quality medical marijuana and the company only delivers to valid medical patients.

Patients across California can now get their orders in less than 45 minutes. Those still using the company's Overnight Delivery Service get their medicine the next day. Pot Valet is expanding its Immediate Delivery Service throughout the United States and soon, patients everywhere will enjoy the same benefits.

To order marijuana delivery through Pot Valet, patients must upload a copy of their Medical Marijuana Recommendation and a government I.D. photograph. The company is fully compliant with state laws and regulations.

DISCLAIMER: The content of this press release is the opinion of Pot Valet, written from the company's perspective.

Pot Valet, LTD

3110 Main Street #304

Santa Monica, California

90405

Office: (800) 357-1314

potvalet.com

Facebook

Twitter

Google+

View original content with multimedia:http://www.prnewswire.com/news-releases/pot-valet-discusses-the-threat-of-trademarked-cannabis-strains-300512014.html

SOURCE Pot Valet

http://potvalet.com

Read the rest here:
Pot Valet Discusses the Threat of Trademarked Cannabis Strains - PR Newswire (press release)

Read More...

Page 943«..1020..942943944945..950960..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick